Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Zhaohui Li, Shihua Li, Yuhai Bi, Yang Yang, Yuhuan Gong, Haixia Xiao, Zheng Fan, Shuguang Tan, Guizhen Wu, Wenjie Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, Jianxun Qi, George Fu Gao, Feng Gao, Lei Liu
doi: https://doi.org/10.1101/2020.05.01.20077743
Yan Wu
1Department of Pathogen Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China
2Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wuy@biols.ac.cn gaofeng@tib.cas.cn gaof@im.ac.cn liulei3322@aliyun.com
Feiran Wang
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
4School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chenguang Shen
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
5Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiyu Peng
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
6College of Veterinary Medicine, China Agricultural University, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delin Li
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
5Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China
7Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Zhao
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
8Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaohui Li
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
9University of Chinese Academy of Sciences, Beijing 100049, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shihua Li
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhai Bi
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
10Center for Influenza Research and Early Warning, Chinese Academy of Sciences (CASCIRE), Beijing 100101, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Yang
5Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhuan Gong
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
10Center for Influenza Research and Early Warning, Chinese Academy of Sciences (CASCIRE), Beijing 100101, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haixia Xiao
7Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Fan
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuguang Tan
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guizhen Wu
11NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenjie Tan
11NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuancheng Lu
12Laboratory Animal Center, Chinese Center for Disease Control and Prevention, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changfa Fan
13Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qihui Wang
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingxia Liu
5Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen Zhang
1Department of Pathogen Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianxun Qi
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Fu Gao
3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wuy@biols.ac.cn gaofeng@tib.cas.cn gaof@im.ac.cn liulei3322@aliyun.com
Feng Gao
7Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wuy@biols.ac.cn gaofeng@tib.cas.cn gaof@im.ac.cn liulei3322@aliyun.com
Lei Liu
5Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People’s Hospital, Shenzhen 518112, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wuy@biols.ac.cn gaofeng@tib.cas.cn gaof@im.ac.cn liulei3322@aliyun.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we report the isolation of four human-origin monoclonal antibodies from a convalescent patient in China. All of these isolated antibodies display neutralization abilities in vitro. Two of them (B38 and H4) block the binding between RBD and vial cellular receptor ACE2. Further competition assay indicates that B38 and H4 recognize different epitopes on the RBD, which is ideal for a virus-targeting mAb-pair to avoid immune escape in the future clinical applications. Moreover, therapeutic study on the mouse model validated that these two antibodies can reduce virus titers in the infected mouse lungs. Structure of RBD-B38 complex revealed that most residues on the epitope are overlapped with the RBD-ACE2 binding interface, which explained the blocking efficacy and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide the structural basis of rational vaccine design.

One Sentence Summary A pair of human neutralizing monoclonal antibodies against COVID-19 compete cellular receptor binding but with different epitopes, and with post-exposure viral load reduction activity.

Competing Interest Statement

Y.W., F.W., C.S., D.L., S.T., Y.L, G.F.G and L.L. are listed as inventors on pending patent applications for mAb B38 and H4. The other authors declare that they have no competing interests.

Funding Statement

This work was supported by Zhejiang University special scientific research fund for COVID-19 prevention and control (2020XGZX019), the National Science and Technology Major Project (2018ZX10733403), the National Key R&D Program of China (2018YFC1200603), the National Key Plan for Scientific Research and Development of China (2016YFD0500304), National Natural Science Foundation of China (81902058), and the National Science and Technology Major Projects of Infectious Disease Funds (2017ZX10304402).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All the data and reagents presented in this study are available from the corresponding authors upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 07, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Zhaohui Li, Shihua Li, Yuhai Bi, Yang Yang, Yuhuan Gong, Haixia Xiao, Zheng Fan, Shuguang Tan, Guizhen Wu, Wenjie Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, Jianxun Qi, George Fu Gao, Feng Gao, Lei Liu
medRxiv 2020.05.01.20077743; doi: https://doi.org/10.1101/2020.05.01.20077743
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Zhaohui Li, Shihua Li, Yuhai Bi, Yang Yang, Yuhuan Gong, Haixia Xiao, Zheng Fan, Shuguang Tan, Guizhen Wu, Wenjie Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, Jianxun Qi, George Fu Gao, Feng Gao, Lei Liu
medRxiv 2020.05.01.20077743; doi: https://doi.org/10.1101/2020.05.01.20077743

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8789)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1863)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (394)
  • Infectious Diseases (except HIV/AIDS) (10565)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1756)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (265)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1845)
  • Public and Global Health (3986)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)